Comparison of Efficacy and Safety of First-Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-Analysis

Figure 4

Rankograms for CRR (a), ORR (b), DCR (c), any TRAEs (d), ≥3 TRAEs (e), any irAEs (f), and ≥3 irAEs (g). CRR: complete response rate; ORR: objective response rate; DCR: disease control rate; TRAEs: treatment-related adverse events; irAEs: immune-related adverse events; camre: camrelizumab; nivo: nivolumab; sinti: sintilimab; tori: toripalimab; tisle: tislelizumab; pembro: pembrolizumab; chemo: chemotherapy.

(a)

(b)

(c)

(d)

(e)

(f)

(g)